Pulmonx Corporation (LUNG)
| Market Cap | 588.30M |
| Revenue (ttm) | 49.96M |
| Net Income (ttm) | -51.39M |
| Shares Out | 37.12M |
| EPS (ttm) | -1.42 |
| PE Ratio | n/a |
| Forward PE | 28.33 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,287,344 |
| Open | 16.28 |
| Previous Close | 15.90 |
| Day's Range | 15.70 - 16.66 |
| 52-Week Range | 13.84 - 45.81 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 30.75 (+94.0%) |
| Earnings Date | Aug 2, 2022 |
About LUNG
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based q... [Read more...]
Financial Performance
In 2021, Pulmonx's revenue was $48.42 million, an increase of 47.91% compared to the previous year's $32.73 million. Losses were -$48.66 million, 51.0% more than in 2020.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for LUNG stock is "Buy." The 12-month stock price forecast is 30.75, which is an increase of 94.01% from the latest price.
News
Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates
Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of -16.22% and 14.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Pulmonx Reports First Quarter 2022 Financial Results
REDWOOD CITY, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported ...
Pulmonx to Present at the Bank of America Securities 2022 Healthcare Conference
REDWOOD CITY, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the comp...
Pulmonx to Report First Quarter 2022 Financial Results on May 3, 2022
REDWOOD CITY, Calif., April 19, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will r...
Pulmonx Corporation (LUNG) Reports Q4 Loss, Lags Revenue Estimates
Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 0% and 3.53%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Pulmonx Reports Fourth Quarter and Full Year 2021 Financial Results
REDWOOD CITY, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported...
Pulmonx to Present at the Citi 2022 Virtual Healthcare Conference
REDWOOD CITY, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the compa...
Pulmonx to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022
REDWOOD CITY, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will re...
Wall Street Analysts See a 53% Upside in Pulmonx Corporation (LUNG): Can the Stock Really Move This High?
The mean of analysts' price targets for Pulmonx Corporation (LUNG) points to a 53% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among ...
Pulmonx to Present at the 40th Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the compa...
Primecap Pumps Up Pulmonx Position
Media-shy investment firm Primecap Management revealed earlier this week it boosted its stake in Pulmonx Corp. ( LUNG , Financial), impacting the equity portfolio by 0.03%.
Pulmonx to Present at the 33rd Annual Piper Sandler Healthcare Conference
REDWOOD CITY, Calif., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the comp...
Pulmonx to Participate at Upcoming Investor Conferences
REDWOOD CITY, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the compa...
Pulmonx Corporation (LUNG) Reports Q3 Loss, Misses Revenue Estimates
Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 24.32% and -0.70%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Pulmonx Reports Third Quarter 2021 Financial Results
REDWOOD CITY, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for severe lung disease, today r...
Pulmonx to Report Third Quarter 2021 Financial Results on November 2, 2021
REDWOOD CITY, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will re...
Can Pulmonx Corporation (LUNG) Climb 43% to Reach the Level Wall Street Analysts Expect?
The consensus price target hints at a 42.8% upside potential for Pulmonx Corporation (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings...
Chief Financial Officer Of Pulmonx Makes $224.56 Thousand Sale
Derrick Sung, Chief Financial Officer at Pulmonx (NASDAQ:LUNG), made a large insider sell on September 21, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exch...
Pulmonx Announces Two Additional Significant Blue Cross Blue Shield Plans Now Provide Coverage for Severe Emphysema/C...
REDWOOD CITY, Calif.--(BUSINESS WIRE)---- $LUNG #COPD--Pulmonx Announces BCBS of Michigan and Horizon BCBS of New Jersey Issue Coverage Policies Providing Coverage for Treatment with the Zephyr® Valve
3 Healthcare Stocks That Might Skyrocket When COVID Is Over
Stocks of biotech companies fighting COVID-19 have been great investments over the last two years. What stocks might zoom higher when the pandemic is over?
Pulmonx to Present at Upcoming September Investor Conferences
REDWOOD CITY, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) today announced the company will be participating in fireside chats at two upcoming virtual investo...
Pulmonx Announces Anthem Blue Cross Blue Shield Now Provides Coverage for Severe COPD/Emphysema Treatment
REDWOOD CITY, Calif.--(BUSINESS WIRE)---- $LUNG #COPD--Positive Coverage Policy Gives Additional 34 Million People Access to Treatment with the Zephyr® Valve, a Minimally Invasive Treatment Option
Pulmonx Reports Second Quarter 2021 Financial Results
REDWOOD CITY, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for severe lung disease, today r...
Pulmonx Welcomes Two New Board Members, Adding Expertise in Health Technology, Consumer Marketing, and Integrated Hea...
Alissa Hsu Lynch and Tiffany Sullivan join the Pulmonx Board of Directors Alissa Hsu Lynch and Tiffany Sullivan join the Pulmonx Board of Directors
Pulmonx Announces Long-Term Follow-Up Data Confirming Significant Benefits of Zephyr Valve for Patients with Severe C...
REDWOOD CITY, Calif.--(BUSINESS WIRE)-- #COPD--Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the publication o...